Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

Clinical trial NCT07231575 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07231575
Sponsor: Sun Yat-sen University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Neoadjuvant Immunotherapy NSCLC Chemo-free Therapy

Start date: 2025-11-10
Primary completion: 2027-11-30
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.